Government Push: India's Excipient Ambition Takes Shape
In order to cut the reliance on Chinese imports and to capture the global market, the Indian government has taken considerable initiatives to tell India’s excipient story.
Key Initiatives:
Production Linked Incentive (PLI) Scheme tops the list. It offers cash incentives to pharma and chemical makers who hit production targets for APIs and excipients, making local manufacturing competitive against imports. Excipient makers can grab bonuses for scaling output, especially for high-margin products like solubility boosters and speciality polymers.
Make in India Campaign pushes domestic capacity with the goal of building plants, creating jobs, and stop bleeding of foreign exchange on imports. Excipients fall squarely in this push, with state governments offering land and tax breaks to set up facilities.
Quality & Certification Push: The USFDA approvals for Indian excipient plants have jumped in recent years—the government funds training, quality audits, and regulatory consulting to help small and mid-size players meet global standards. More approvals mean bigger export orders.
R&D Support through schemes like CSIR and DSIR funding helps companies develop novel excipients—green cellulose, plant-based binders, solubility tech—keeping India ahead of cheap copycat competitors.
India's excipient makers are focusing on turning a commodity into an established and highly valued industry. They're focusing on getting the backing to innovate, scale, and go global.
India's Excipient Champions: Who's Leading the Charge
One or two giants don't dominate India's excipient scene—it's a mix of established players, smart mid-size operators, and scrappy innovators all fighting for share. Here are some of the major players in the Indian excipient industry.
Patel Chem Specialities, where Venture X is invested in, is one of the most recognised excipient players in India. Based in Ahmedabad, they've built branded excipients like Blowtab (sodium starch glycolate), Hindcell (microcrystalline cellulose), Rheollose (sodium CMC), Disolwell (croscarmellose sodium), and Swellcal (calcium CMC). Their strategy remains focused on high-quality & assured pharma-grade versions of common excipients with strong technical support. They export globally and are a go-to for tablet makers.
The company’s primary growth strategy is to establish a new manufacturing facility at Indrad, Mehsana, with a capital expenditure of ₹43.15 crore from the IPO proceeds. This facility will specialise in high-demand speciality excipients: Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG), and Calcium Carboxymethyl Cellulose (CMC). The new plant is expected to be commercialised by March 2026 and will add 6,012 MTPA to its total installed capacity, bringing total capacity from 3,720 MTPA to 9,732 MTPA.
Apart from that, the company is already exporting to over 15 countries, including the USA, Germany, UK, Japan, China, and Australia and plans to strengthen its international presence by building stronger distribution networks, advancing R&D to address diverse market needs, and exploring opportunities in new and emerging regions.
The company is positioned to capitalise on the growing demand for speciality excipients in pharmaceuticals, nutraceuticals, and food industries while maintaining its strong margins through value-added product focus.
Accent Microcell- Where Venture X is invested in, specialises in microcrystalline cellulose (MCC) and cellulose-based excipients. They're known for consistent particle size, flow properties, and purity—critical for tablet compression. Their MCC grades serve both the pharma and food industries, and they've built a solid reputation for reliability among domestic and export customers.
The company is moving towards a value-led speciality excipients and prioritising high-margin products like CMC. On the international front, Accent is securing regulatory approvals, particularly EXCiPACT certification for Europe, which will progressively scale its international presence in American and European markets.
Beyond capacity, they're investing in advanced manufacturing technologies, process optimisation, and product innovation to develop customised solutions across diverse industries. Their strategic blueprint emphasises expanding into new sectors—cosmetics, personal care, beverages, e-cigarettes, textiles, leather, and dairy—while targeting key customer segments including pharma companies, nutraceutical firms, generic drug manufacturers, and CDMOs/CMOs.
Apart from that, there are also other emerging players in the Indian market, such as:
Gangwal Chemicals specialises in cost-competitive cellulose derivatives and disintegrants for India's generic drug makers. With solid USFDA approvals, they thrive on volume and operational efficiency in commodity segments. Challenge: margin compression from Chinese competition; opportunity lies in diversifying into speciality products.
Megafine Speciality Chemicals produces starch derivatives, CMC, and MCC for both pharma and food industries, positioning themselves as the reliable mid-tier option. Known for consistent quality and reasonable pricing, they serve small to mid-sized formulators. Their growth strategy is organic—steady expansion while reducing pharma concentration risk through food sector diversification.
Spectrum Pharma focuses on speciality polymers and modified-release excipients (enteric coatings, sustained-release binders) commanding 3-5x margin premiums. Export-focused with multinational pharma relationships, they benefit from the global shift toward modified-release formulations. Risk: innovation dependence; opportunity: rising demand for complex, customised excipients.
Supriya Lifescience is the smallest but most specialised player, focusing on lipid-based excipients and bioavailability enhancers for hard-to-dissolve drugs. High margins (20%+) but limited scale. Strategy: build R&D credibility and secure regulatory approvals to capture the fast-growing bioavailability enhancement segment.
Most Indian players stick to volume basics (MCC, starch derivatives) where margins are tight but volumes are huge. A few, like Patel Chem and Accent Microcell, have built solid reputations for quality. The real growth happens when smaller players get USFDA approval and start exporting—that's where the real money is.
Talking about the foreign market, players like Roquette and BASF have set up or expanded Indian operations to leverage low-cost raw materials, skilled labour, and proximity to Asia-Pacific pharma hubs. These MNCs serve both local Indian demand and export to regulated markets, bringing global R&D, quality standards, and brand credibility while pressuring local players to match their scale, technology, and compliance capabilities.